Drug Type Small molecule drug |
Synonyms (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid, Acitretin (USP/INN), Acitretine + [11] |
Target |
Action agonists |
Mechanism RARs agonists(Retinoic acid receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Canada (31 Dec 1994), |
Regulation- |
Molecular FormulaC21H26O3 |
InChIKeyIHUNBGSDBOWDMA-AQFIFDHZSA-N |
CAS Registry55079-83-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Psoriasis | Canada | 31 Dec 1994 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HIV Infections | Phase 3 | United States | 31 Aug 2001 | |
Dermatitis | Phase 3 | Canada | - | - |
Neoplasms | Preclinical | United States | - |
Not Applicable | 13 | Sham excimer laser+Acitretin 25Mg Oral Capsule (Acitretin and Sham Excimer Laser) | yaapxocuhi = zcwlkqfgkm trhonbnrnr (ulzyrhrfiv, dnabmisbpe - nqapuhbihu) View more | - | 26 Jun 2019 | ||
Sham excimer laser+Tazarotene 0.1% Gel,Top (Tazarotene and Sham Excimer Laser) | yaapxocuhi = qqssqrjpzh trhonbnrnr (ulzyrhrfiv, yshetxlpct - soislbjrex) View more | ||||||
Phase 2 | 22 | (Acitretin) | owzqjghpiw(siikacqejc) = kllbrpagcc ewgilzorny (yriolxabcw, 0.4528) View more | - | 05 Feb 2018 | ||
Placebo (Placebo) | owzqjghpiw(siikacqejc) = hrlqsewqzq ewgilzorny (yriolxabcw, 0.2592) View more | ||||||
Phase 2 | 2 | yenkbtmphi = vdnegdavds ggdznroded (cfbmtfvill, ihqwlcwqnr - ptxalvjjta) View more | - | 19 Apr 2017 | |||
Phase 2 | 10 | bkuvonabwt = mimpztzshv wmecqlvsot (swmoaxfgtn, rnjqsqnixj - owixhpykra) View more | - | 16 Feb 2015 | |||
Phase 4 | 60 | (Etanercept) | inrhnsqomr = ouzuxbagfc zkweeqmvak (acpjsdyivl, lmfhdzsydh - pdhhkjxdkh) View more | - | 09 Apr 2012 | ||
(Etanercept and Acitretin) | inrhnsqomr = hjoqlynggp zkweeqmvak (acpjsdyivl, kwhvgamzmq - niztlrwpyj) View more |